I amuse I'm stating the obvious here but that pilot XOMA's trial was an open, uncontrolled, in 7 patients only, in Turkey (http://ard.bmj.com/content/71/4/563.abstract). For the sake of comparison, this is AMGN's Kineret (a different anti IL-1 antibody, which is behind XOMA in Behçet’s disease) pilot trial - randomized, controlled, in 25 patients in US:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.